Credit Suisse upgraded Novozymes to Neutral from Underperform with an unchanged price target of DKK 340. The analyst cites the shared price underperformance since the announcement of the proposed Christian Hansen and "attainable" fiscal 2023 growth targets for the upgrade.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVZMY:
